Clinical trials: Obesity & Overweight
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with…
- Trial name
- NCT04483947
- Testing
- AZD2693
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Overweight (BMI > 25), Obesity & Overweight
Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.
We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.
- Trial name
- GLOBE (NCT07229027)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Medialis Ltd.
Obesity (Disorder), Obesity & Overweight
Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).
- Conditions
- Obesity (Disorder), Obesity & Overweight, Type 2 Diabetes (T2DM)
- Trial name
- MAGvMED (NCT07317115)
- Testing
- Magnet System, Semaglutide
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- GT Metabolic Solutions, Inc.
Obesity, Obese
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
- Conditions
- Obesity, Obese, Overweight or Obesity
- Trial name
- NCT05616013
- Testing
- Bimagrumab, Semaglutide
- Where
- 26 sites in United States, Australia and 1 more
- Volunteers
- 507 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
The primary objective of this study is to determine the efficacy of oral KAI-7535 once daily compared with placebo on percent change in body weight in participants living with obesity or overweight, with at least 1 weight-related…
- Trial name
- NCT07497880
- Testing
- KAI-7535
- Where
- 36 sites in United States, Australia
- Volunteers
- 306 people
- Sponsor
- Kailera
Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese…
- Trial name
- NCT06628362
- Testing
- Enicepatide
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 447 people
- Sponsor
- Carmot Therapeutics, Inc.
Obesity Hypoventilation Syndrome
Target Volume Mode Controlled Ventilator in Obesity Hypoventilation Syndrome
The purpose of this study is to investigate the evolution of daytime partial pressure of carbon dioxide in the blood (PaCO2) after 6 weeks of noninvasive ventilation-pressure support ventilation (NIV-PSV) with target volume…
- Trial name
- OVO (NCT01104610)
- Testing
- Breas Vivo 40
- Where
- 2 sites in France
- Sponsor
- Breas Medical S.A.R.L.
Obesity
Endostapler Sleeve Gastrectomy Study
The goal of this prospective, post-market study is to measure AEON™ Endostapler performance for laparoscopic sleeve gastrectomy surgery versus the Endo GIA™ Reloads with Tri-Staple™ Technology from Medtronic.
- Trial name
- NCT04617574
- Testing
- AEON Endostapler, Endo GIA Reloads with Tri-Staple Technology
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Lexington Medical Inc.
Obesity & Overweight
Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy
A pragmatic, randomized, parallel-arm, controlled study of weight loss outcomes using AOMs guided by MyPhenome test.
- Trial name
- PhenoRXPrag (NCT07728812)
- Testing
- Genetic Test, Anti-Obesity Medication (AOM) treatment
- Volunteers
- 424 people
- Sponsor
- Phenomix Sciences
Obesity, Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy
The purpose of this study is to compare the effectiveness and safety of topiramate with placebo in the treatment of obesity and Type 2 diabetes mellitus in patients who have failed on sulfonylurea therapy.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231634
- Testing
- topiramate
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight, Obesity
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes.
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04407234
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Hypothalamic Obesity
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients
The extension protocol is designed to allow those patients randomized to placebo in the core portion of the protocol to receive a 6 month treatment of open label octreotide and allow those patients randomized to octreotide who…
- Trial name
- NCT00171613
- Testing
- Octreotide
- Volunteers
- 32 people
- Sponsor
- Novartis
Obesity
A Feasibility Study for the Treatment of Primary Obesity
This study has been expanded to a four center, open-label, 2-group randomized pilot study evaluating a treatment for obesity.
- Trial name
- NCT03837691
- Testing
- Placement of Snowshoe Suture Anchors, Moderate Intensity Diet & Exercise Program
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- USGI Medical
Obesity
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
- Trial name
- KaiNETIC-3 (NCT07284979)
- Testing
- Ribupatide, Semaglutide
- Where
- 60 sites in United States, Australia and 3 more
- Volunteers
- 1,270 people
- Sponsor
- Kailera
Insulin Resistance, Obesity
A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes
The purpose of this study is to determine whether the investigational drug INCB013739 has an effect on systemic and adipose tissue 11-HSD1 activity in obese, insulin resistant subjects.
- Trial name
- NCT00398619
- Testing
- INCB13739
- Where
- 2 sites in United States
- Sponsor
- Incyte Corporation
Binge Eating Disorder, Obesity
A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder
The purpose of this study is to examine the safety and efficacy of sibutramine in preventing binge eating episodes. Additionally the study aim is to evaluate the safety and efficacy of sibutramine in reducing body weight in…
- Trial name
- NCT00402584
- Testing
- sibutramine
- Volunteers
- 304 people
- Sponsor
- Abbott
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
- Conditions
- Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes
- Trial name
- TREASURE-CKD (NCT05536804)
- Testing
- Tirzepatide
- Where
- 27 sites in United States, Austria and 4 more
- Volunteers
- 134 people
- Sponsor
- Eli Lilly and Company
Overweight and Obesity, Weight Loss
Study to Evaluate Effects of a Weight Loss Program in Different Formats on Healthy Adults
The objective of this study was to determine changes in body weight and related outcomes achievable over a 16-week period in response to three different commercially available weight loss programs (Nutrisystem) providing…
- Trial name
- NCT03017443
- Testing
- Nutrisystem Turbo 10, Nutrisystem My Way, Nutrisystem DASH
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Nutrisystem, Inc.
Overweight, Obesity
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study.
- Trial name
- NCT03856047
- Testing
- NNC0174-0833, Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 8 more
- Volunteers
- 706 people
- Sponsor
- Novo Nordisk A/S
Obesity
Effects of Synbiotics on Obesity
Synbiotics are a combination of probiotics and prebiotics that can promote the survival of probiotics in the gut. Probiotics utilize prebiotics to produce various metabolites beneficial to human health, such as short-chain fatty…
- Trial name
- NCT06578143
- Testing
- Synbiotics
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Leeuwenhoek Laboratories Co. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.